AJANTA PHARMA
|
AJANTA PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 73.69 | 64.83 | 46.70 | 83.45 | 75.59 |
| CEPS(Rs) | 85.23 | 75.58 | 57.09 | 65.42 | 59.34 |
| DPS(Rs) | 28.00 | 51.00 | 7.00 | 9.50 | 9.50 |
| Book NAV/Share(Rs) | 303.04 | 282.89 | 269.07 | 382.20 | 346.24 |
| Tax Rate(%) | 22.60 | 26.73 | 21.10 | 21.64 | 27.36 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.15 | 14.69 | 10.93 | 27.37 | 33.85 |
| EBIT Margin(%) | 13.59 | 14.05 | 10.48 | 27.09 | 30.80 |
| Pre Tax Margin(%) | 13.36 | 13.96 | 10.40 | 26.78 | 30.52 |
| PAT Margin (%) | 10.34 | 10.23 | 8.20 | 20.99 | 22.17 |
| Cash Profit Margin (%) | 11.96 | 11.93 | 10.03 | 24.68 | 26.10 |
| Performance Ratios | |||||
| ROA(%) | 19.72 | 17.73 | 13.21 | 17.16 | 17.03 |
| ROE(%) | 25.06 | 23.49 | 17.68 | 22.77 | 23.38 |
| ROCE(%) | 32.87 | 32.22 | 22.57 | 29.37 | 32.20 |
| Asset Turnover(x) | 1.91 | 1.73 | 1.61 | 0.82 | 0.77 |
| Sales/Fixed Asset(x) | 3.43 | 3.42 | 3.19 | 1.56 | 1.44 |
| Working Capital/Sales(x) | 4.86 | 4.37 | 4.25 | 2.10 | 2.14 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.29 | 0.29 | 0.31 | 0.64 | 0.69 |
| Receivable days | 49.80 | 52.69 | 52.87 | 94.50 | 93.66 |
| Inventory Days | 35.51 | 37.60 | 40.91 | 83.71 | 78.09 |
| Payable days | 187.66 | 183.71 | 157.44 | 188.77 | 260.89 |
| Valuation Parameters | |||||
| PER(x) | 35.53 | 34.52 | 25.89 | 14.45 | 15.82 |
| PCE(x) | 30.72 | 29.61 | 21.18 | 18.44 | 20.15 |
| Price/Book(x) | 8.64 | 7.91 | 4.49 | 4.73 | 5.18 |
| Yield(%) | 1.07 | 2.28 | 0.58 | 0.53 | 0.53 |
| EV/Net Sales(x) | 7.00 | 6.66 | 3.98 | 4.56 | 5.30 |
| EV/Core EBITDA(x) | 24.03 | 22.32 | 16.89 | 14.58 | 14.94 |
| EV/EBIT(x) | 26.89 | 25.02 | 19.83 | 16.57 | 16.85 |
| EV/CE(x) | 8.58 | 7.86 | 4.39 | 3.63 | 3.72 |
| M Cap / Sales | 7.04 | 6.70 | 4.07 | 4.62 | 5.37 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.44 | 12.45 | 12.02 | 15.62 | 11.66 |
| Core EBITDA Growth(%) | 7.76 | 42.48 | -15.61 | 1.99 | 32.11 |
| EBIT Growth(%) | 7.92 | 49.27 | -18.33 | 1.24 | 34.41 |
| PAT Growth(%) | 12.77 | 38.81 | -17.50 | 8.99 | 39.81 |
| EPS Growth(%) | 13.67 | 38.81 | -44.04 | 10.40 | 41.02 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 2.84 | 3.04 | 2.48 | 3.50 | 2.64 |
| Quick Ratio(x) | 1.94 | 2.12 | 1.77 | 2.31 | 1.74 |
| Interest Cover(x) | 58.36 | 155.50 | 128.61 | 90.16 | 109.85 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of AJANTA PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AJANTA PHARMA | ₹32,616.4 Cr | 6.1% | 8.7% | -15.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹406,147.0 Cr | -1.4% | 3.6% | -7.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹180,488.0 Cr | 4.4% | 15.9% | 15.6% | Stock Analytics | |
| CIPLA | ₹121,452.0 Cr | -4.9% | -0.8% | 6.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,057.0 Cr | -0.6% | 1.8% | 15.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,220.0 Cr | -4.1% | -3.8% | -4.3% | Stock Analytics | |
AJANTA PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | 6.1% |
8.7% |
-15.2% |
| SENSEX | -1.4% |
3.1% |
3.8% |
You may also like the below Video Courses
